Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

In this episode, Dr Brad Kahl and Dr Noopur Raje discuss the recent advances and emerging data for CAR T-cell therapy in lymphomas and multiple myeloma including the latest evidence from long-term clinical trial follow-up and real-world data, plus new data with CAR T-cell therapies in new lymphoma settings and novel CAR T-cell therapies currently under development for multiple myeloma.<ul><li>Lymphomas<ul><li>DLBCL: Real-world outcomes post axi-cel, CAR T vs autologous HSCT</li><li>FL: Tisa-cel (ELARA), axi-cel (ZUMA-5)</li><li>MZL: Liso-cel (TRANSCEND FL)</li><li>MCL: Real-world outcomes post brexu-cel</li><li>CLL: Liso-cel (TRANSCEND CLL 004)</li></ul></li><li>Multiple Myeloma<ul><li>Cilta-cel (CARTITUDE-1)</li><li>Anito-cel (iMMagine-1)</li><li>GC012F</li><li>Arlo-cel</li><li>BMS-986453</li><li>TriPRIL  </li></ul></li></ul>Presenters:Brad Kahl, MD Professor of Medicine Washington University  St Louis, MissouriNoopur Raje, MD  Director, Center for Multiple Myeloma Massachusetts General Hospital Cancer Center Professor of Medicine Harvard Medical School Boston, Massachusetts  Content based on an online CME program supported by an independent educational grant from Bristol Myers Squibb.Link to full program:  <a href="https://bit.ly/3ViR62V" target="_blank">https://bit.ly/3ViR62V</a>

CCO Oncology Podcast

Latest Advances in CAR T-Cell Therapy for Lymphomas and Multiple Myeloma

In this episode, Drs William J. Gradishar, Heather McArthur, and Joanne Mortimer address audience questions from a recent live event on the use of CDK4/6 inhibitors in patients with early and metastatic breast cancer, including:<ul><li>Genomic testing options for assessing risk of recurrence</li><li>Adjuvant treatment duration and holidays with CDK4/6 inhibitors</li><li>Managing renal toxicities, prophylaxis for DVT, and asymptomatic ILD</li><li>CDK4/6 inhibitors with inavolisib and fulvestrant</li></ul>Presenters: William J. Gradishar, MD, FACP, FASCO Betsy Bramsen Professor of Breast Oncology Robert H. Lurie Comprehensive Cancer Center Northwestern University Chicago, IllinoisHeather McArthur, MD, MPH, FASCO Professor, Department of Internal Medicine Clinical Director, Breast Cancer Program Komen Distinguished Chair in Clinical Breast Cancer Research UT Southwestern Medical Center Dallas, TexasJoanne Mortimer, MD, FACP, FASCO Vice Chair, Medical Oncology Professor, Division of Medical Oncology & Experimental Therapeutics Associate Director for Education and Training Baum Family Professor of Women’s Cancers City of Hope Comprehensive Cancer Center Duarte, CaliforniaLink to full program: <a href="https://bit.ly/4osHLTm" target="_blank">https://bit.ly/4osHLTm</a>

CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Experts Answer Your Questions

In this episode, Dr. Daniel Morgensztern and Dr. Jonathan Strosberg discuss the emerging role of DLL3-targeted agents in the management of extrapulmonary neuroendocrine carcinomas, including:<ul><li>The clinical implications of using DLL3 as a therapeutic target</li><li>The impact of emerging DLL3-targeted therapies on evolving treatment paradigms</li><li>How to incorporate DLL3-based treatments into clinical practice</li></ul>Presenters:Daniel Morgensztern, MD Professor of Medicine Clinical Director of Thoracic Oncology Washington University School of Medicine St Louis, MissouriJonathan Strosberg, MD Professor Department of GI Oncology Moffitt Cancer Center and Research Institute Tampa, FloridaContent based on an online CME program supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Link to full program:  <a href="https://bit.ly/4mjNPfy" target="_blank">https://bit.ly/4mjNPfy</a>

Emerging DLL3-Targeted Therapies for Extrapulmonary Neuroendocrine Carcinomas

In this episode, listen to Kelly Romo, PharmD, BCOP; and Shauna Kraft, PharmD, BCOP, share their takeaways from a live webinar on available emerging subcutaneous immunotherapy options for patients with cancer including:<ul><li>Basic mechanism of action and role of hyaluronidase in subcutaneous immunotherapy formulation and available dosing/schedules</li><li>Available pharmacodynamics/pharmacokinetics, efficacy, and safety data for subcutaneous immunotherapy formulations</li><li>Current and potential models for administration of subcutaneous immunotherapy in the inpatient setting and day-to-day considerations</li></ul>Presenters:Kelly Romo, PharmD, BCOP Manager, Oncology Medical Drug Management and Customer Initiatives Blue Cross Blue Shield Michigan Detroit, MichiganShawna Kraft, PharmD, BCOP Clinical Pharmacist, Specialist Michigan Medicine, Rogel Cancer Center Clinical Associate Professor University of Michigan College of Pharmacy Ann Arbor, MichiganResources: Consolidate your learning with a recording from an <a href="https://bit.ly/4mdczGb" target="_blank">on-demand webcast</a>, download the <a href="https://bit.ly/45xwAAf" target="_blank">slides</a> associated with this discussion, or read an expert <a href="https://bit.ly/45qrMMU" target="_blank">text module</a> or <a href="https://bit.ly/45qrMMU" target="_blank">commentary</a> on this topic.

Clinical Care Options

CCO Oncology Podcast by Clinical Care Options

Episodes